

PATENT APPLICATION TRANSMITTAL LETTER
(Large Entity)

Docket No.
1038-865 MIS

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Transmitted herewith for filing under 35 U.S.C. 111 and 37 C.F.R. 1.53 is the patent application of:

Connaught Laboratories Limited

For:

ALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES

Enclosed are:

- ☐ Certificate of Mailing with Express Mail Mailing Label No.
☐ sheets of drawings.
☐ A certified copy of a application.
☐ Declaration ☐ Signed. ☐ Unsigned.
☐ Power of Attorney
☐ Information Disclosure Statement
☐ Preliminary Amendment
☐ Other:

jc518 U.S. PTO
09/190246
11/13/98

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	38	- 20 =	18	x \$22.00	\$396.00
Indep. Claims	3	- 3 =	0	x \$82.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$790.00
TOTAL FILING FEE					\$1,186.00

- ☒ A check in the amount of \$1,186.00 to cover the filing fee is enclosed.
☐ The Commissioner is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed.
☐ Charge the amount of as filing fee.
☐ Credit any overpayment.
☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: November 13, 1998

M. L. Stewart
Signature

cc:

MIS 1038-864 1998 11 13 D2

TITLE OF INVENTION

ALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES

5

FIELD OF INVENTION

The present invention relates to the field of paramyxoviridae vaccines and is particularly concerned with vaccines comprising DNA encoding the fusion (F) protein of respiratory syncytial virus (RSV) in an alphavirus vector.

BACKGROUND OF THE INVENTION

Human respiratory syncytial virus (RSV) has been identified as a major pathogen responsible for severe respiratory tract infections in infants, young children and the institutionalized elderly (refs. 1,2,3,4 - throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). Global mortality and morbidity figures indicate that there is an urgent need for an efficacious RSV vaccine (refs. 5,6). In the USA alone, approximately 100,000 children are hospitalized annually with severe cases of pneumonia and bronchiolitis resulting from an RSV infection. Inpatient and ambulatory care for children with RSV infections has been estimated to cost in excess of \$340 million each year in the USA. The World Health Organization (WHO) and the National Institute of Allergy and Infectious Disease (NIAID) vaccine advisory

2

committees have ranked RSV second only to HIV for vaccine development. Both the annual morbidity and mortality figures as well as the staggering health care costs for managing RSV infections have provided the incentive for aggressively pursuing the development of efficacious RSV vaccines. However, such a vaccine is still not available.

Formalin-inactivated (FI-RSV) and live attenuated RSV vaccines have failed to demonstrate efficacy in clinical trials (refs. 7,8,9,10). Moreover, the formalin-inactivated RSV vaccine caused enhanced disease in some children following exposure to wild-type RSV (refs. 7,8,9,10). Elucidation of the mechanism(s) involved in the potentiation of RSV disease is important for the design of safe RSV vaccines, especially for the seronegative population. Recent experimental evidence suggests that an imbalance in cell-mediated responses may contribute to immunopotential. Enhanced histopathology observed in mice that were immunized with the FI-RSV and challenged with virus could be abrogated by depletion of CD4+ cells or both interleukin-4 (IL-4) and IL-10.

The RSV fusion (F) glycoprotein is one of the major immunogenic proteins of the virus. This envelope glycoprotein mediates both fusion of the virus to the host cell membrane and cell-to-cell spread of the virus (ref. 1). The F protein is synthesized as a precursor (F₀) molecule which is proteolytically cleaved to form a disulphide-linked dimer composed of the N-terminal F₂ and C-terminal F₁ moieties (ref. 11). The amino acid sequence of the F protein is highly conserved among RSV

09190245-11398
B6ETT-9420260

3

subgroups A and B and is a cross-protective antigen (refs. 6,12). In the baculovirus expression system, a truncated secreted version of the RSV F protein has been expressed in *Trichoplusia ni* insect cells (ref. 13). The
5 recombinant protein was demonstrated to be protective in the cotton rats (ref. 13).

Studies on the development of live viral vaccines and glycoprotein subunit vaccines against parainfluenza virus infection are being pursued. Clinical trial
10 results with a formalin-inactivated PIV types 1,2,3 vaccine demonstrated that this vaccine was not efficacious (refs. 14, 15, 16). Further development of chemically-inactivated vaccines was discontinued after clinical trials with a formalin-inactivated RSV vaccine
15 demonstrated that not only was the vaccine not effective in preventing RSV infection but many of the vaccinees who later become infected with RSV suffered a more serious disease. Most of parainfluenza vaccine research has focused on candidate PIV-3 vaccines (ref. 17) with
20 significantly less work being reported for PIV-1 and PIV-2. Recent approaches to PIV-3 vaccines have included the use of the closely related bovine parainfluenza virus type 3 and the generation of attenuated viruses by cold-adaptation of the virus
25 (refs. 18, 19, 20, 21).

Another approach to parainfluenza virus type 3 vaccine development is a subunit approach focusing on the surface glycoproteins hemagglutinin-neuraminidase (HN) and the fusion (F) protein (refs. 22, 23, 24). The
30 HN antigen, a typical type II glycoprotein, exhibits both haemagglutination and neuraminidase activities and

09190246 44380
86E7F7 94206160

4

is responsible for the attachment of the virus to sialic acid containing host cell receptors. The type I F glycoprotein mediates fusion of the viral envelope with the cell membrane as well as cell to cell spread of the virus. It has recently been demonstrated that both the HN and F glycoproteins are required for membrane fusion. The F glycoprotein is synthesized as an inactive precursor (F) which is proteolytically cleaved into disulfide-linked F2 and F1 moieties. While the HN and F proteins of PIV-1, -2 and -3 are structurally similar, they are antigenically distinct. Neutralizing antibodies against the HN and F proteins of one of PIV type are not cross-protective. Thus, an effective PIV subunit vaccine must contain the HN and F glycoproteins from the three different types of parainfluenza viruses. Antibody to either glycoprotein is neutralizing in vitro. A direct correlation has been observed between the level of neutralizing antibody titres and resistance to PIV-3 infections in infants. Native subunit vaccines for parainfluenza virus type 3 have investigated the protectiveness of the two surface glycoproteins. Typically, the glycoproteins are extracted from virus using non-ionic detergents and further purified using lectin affinity or immunoaffinity chromatographic methods. However, neither of these techniques may be entirely suitable for large scale production of vaccines under all circumstances. In small animal protection models (hamsters and cotton rats), immunization with the glycoproteins was demonstrated to prevent infection with live PIV-3 (refs. 25, 26, 27, 28, 29).

09190246-11398

5

The HN and F glycoproteins of PIV-3 have also been produced using recombinant DNA technology. HN and F glycoproteins have been produced in insect cells using the baculovirus expression system and by use of vaccinia virus and adenovirus recombinants (refs. 30, 31, 32, 33, 34). In the baculovirus expression system, both full-length and truncated forms of the PIV-3 glycoproteins as well as a chimeric F-HN fusion protein have been expressed. The recombinant proteins have been demonstrated to be protective in small animal models (see WO91/00104, US Application No. 07/773,949 filed November 29, 1991, assigned to the assignee hereof).

Semliki Forest virus (SFV) is a member of the Alphavirus genus in the Togaviridae family. The mature virus particle contains a single copy of a ssRNA genome with a positive polarity that is 5'-capped and 3'-polyadenylated. It functions as an mRNA and naked RNA can start an infection when introduced into cells. Upon infection/transfection, the 5' two-thirds of the genome is translated into a polyprotein that is processed into the four nonstructural proteins (nsP1 to 4) by self cleavage. Once the ns proteins have been synthesized they are responsible for replicating the plus-strand (42S) genome into full-length minus strands (ref. 14). These minus-strands then serve as templates for the synthesis of new plus-strand (42S) genomes and the 26S subgenomic mRNA (ref. 14). This subgenomic mRNA, which is colinear with the last one-third of the genome, encodes the SFV structural proteins.

In 1991 Liljestrom and Garoff (ref. 15) designed a series of expression vectors based on the SFV cDNA

00190245-11398

6

replicon. These vectors had the virus structural protein genes deleted to make the way for heterologous inserts, but preserved the nonstructural coding region for production of the nsP1 to 4 replicase complex.

5 Short 5' and 3' sequence elements required for RNA replication were also preserved. A polylinker site was inserted downstream from the 26S promoter followed by translation stop sites in all three frames. An SpeI site was inserted just after the 3' end of the SFV cDNA
10 for linearization of the plasmid for use in vitro transcription reactions.

Injection of SFV RNA encoding a heterologous protein have been shown to result in the expression of the foreign protein and the induction of antibody in a
15 number of studies (refs. 16,17). The use of SFV RNA inoculation to express foreign proteins for the purpose of immunization would have several of the advantages associated with plasmid DNA immunization. For example, SFV RNA encoding a viral antigen may be introduced in
20 the presence of antibody to that virus without a loss in potency due to neutralization by antibodies to the virus. Also, because the protein is expressed in vivo the protein should have the same conformation as the protein expressed by the virus itself. Therefore,
25 concerns about conformational changes which could occur during protein purification leading to a loss in immunogenicity, protective epitopes and possibly immunopotential, could be avoided by plasmid DNA immunization.

30 In copending US Patent Application No. 08/476,397 filed June 7, 1995, assigned to the assignee hereof and

09190246 11398
SECRET 94206T60

7

the disclosure of which is incorporated herein by reference (WO96/040945), there is described reference the use of plasmid vectors containing RSV F protein-encoding DNA for DNA immunization against RSV infection.

5 In copending United States Patent Application No. 08/896,500 filed July 18, 1997, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference, there is described the use of plasmid vectors containing RSV G protein-encoding DNA
10 for DNA immunization against RSV infection.

In my copending United States Patent Application No. 08/923,558, filed September 4, 1997, assigned to the assignee hereof and the disclosure of which is incorporated by reference, I describe a DNA vector using
15 an alphavirus vector, including Semliki Forest virus vector, containing a DNA sequence encoding a paramyxovirus protein, specifically RSV-F, for making an RNA transcript for immunization.

In WO95/27044, the disclosure of which is
20 incorporated herein by reference, there is described the use of alphavirus cDNA vectors based on cDNA complementary to the alphavirus RNA sequence. Once transcribed from the cDNA under transcriptional control of a heterologous promoter, the alphavirus RNA is able
25 to self-replicate by means of its own replicase and thereby amplify the copy number of the transcribed recombinant RNA molecules.

Infection with RSV leads to serious disease. It would be useful and desirable to provide improved
30 vectors for in vivo administration of immunogenic preparations, including vaccines, for protection against

00190246 11390
00000000 00000000

8

disease caused by RSV and other paramyxoviruses. In particular, it would be desirable to provide vaccines that are immunogenic and protective in humans, including seronegative infants, that do not cause disease enhancement (immunopotentialiation).

SUMMARY OF THE INVENTION

The present invention provides novel immunogenic materials and immunization procedures based on such novel materials for immunizing against disease caused by respiratory syncytial virus. In particular, the present invention is directed towards the provision of DNA vaccines against disease caused by infection with paramyxoviridae.

In accordance with one aspect of the present invention, there is provided a vector, comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; a second DNA sequence encoding a paramyxovirus protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication; the first and second DNA sequences being under transcriptional control of a promoter; and a third DNA sequence located adjacent the second DNA sequence to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.

00190246-1139
SECRET-94206160

9

The paramyxovirus protein may be selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial virus (RSV). The PIV protein may be from PIV-1, PIV-2, PIV-3 or PIV-4, particularly the
5 HN and F glycoproteins of PIV-3. The RSV protein particularly may be the F or G glycoprotein of RSV.

The second DNA sequence may encode a full length RSV F protein, or may encode a RSV F protein lacking the transmembrane anchor and cytoplasmic tail. The
10 lack of the coding region for the transmembrane anchor and cytoplasmic tail results in a secreted form of the RSV F protein. Alternatively, as described in the aforementioned U.S. Patent Application 08/896,500, the second DNA sequence may encode the full-length RSV-G
15 protein or a truncated RSV G protein lacking a transmembrane region, resulting in a secreted form of the protein.

The alphavirus preferably is a Semliki Forest virus and the first DNA sequence is the Semliki Forest viral
20 sequence contained in plasmid pSFVI.

The third nucleotide sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing, *in vivo*, whereby substantially all transcribed mRNA from the vector upon administration encodes the RSV protein.
25 Such third nucleotide sequence is preferably located between the first nucleotide sequence and the promoter sequence. Such third nucleotide sequence may be that of rabbit β -globin intron II, as shown in Figure 8 of copending U.S. Patent Application No. 08/476,397 (WO
30 96/040945).

09190246 44399
06CTT 94206160

10

The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter. The human cytomegalovirus Intron A sequence may be provided downstream of the promoter and upstream of the third
5 nucleotide sequence.

A vector encoding the F protein and provided in accordance with one embodiment of the invention may be specifically pMP44, having the identifying characteristics shown in Figure 1D.

10 The vectors provided herein may be used to immunize a host against RSV infection or disease by in vivo expression of RSV F protein or RSV G protein, which may lack a transmembrane region, or other paramyxovirus protein, following administration of the vectors. In
15 accordance with a further aspect of the present invention, therefore, there is provided a method of immunizing a host against disease caused by infection with respiratory syncytial virus or other paramyxovirus, which comprises administering to the host an effective
20 amount of a vector provided herein.

The present invention also includes a novel method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of generating antibodies which specifically react with RSV F or G
25 protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises isolating the gene; operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the
30 complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-

00190246-11300

11

essential for replication to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; operatively linking the gene to an immunoprotection enhancing sequence to produce an enhanced immunoprotection by the RSV F or G protein in the host, preferably by introducing the immunoprotection enhancing sequence between the control sequence and the alphavirus sequence; and introducing the vector into the host. A corresponding procedure may be used for other paramyxoviridae.

In addition, the present invention includes a method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent; operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; operatively linking the first nucleotide sequence to a third nucleotide sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* from the vector in a host; and formulating the vector as a vaccine for *in vivo* administration. A corresponding procedure may be used for other paramyxoviridae.

09190246 11398

12

The present invention further includes a vaccine for administration to a host, including a human host, produced by the method as well as immunogenic compositions comprising an immunoeffective amount of the
5 vectors described herein.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A to 1B show a schematic of a procedure of assembly of vector pMP44;

Figures 2A to 2B show a schematic of a procedure of
10 assembly of vector pMP44;

Figures 3A to 3E contain the nucleotide sequence of plasmid pMP44 (SEQ ID NO:1);

Figure 4 shows the anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after
15 boosting;

Figure 5 shows the nucleotide sequence for a synthetic oligonucleotide coding for the hepatitis delta ribozyme (SEQ ID no; 2.3); and

Figures 6A to 6C show the nucleotide sequence for
20 the SFV EcoRV-SpeI fragment ligated to the ribozyme of
Figure 5 (SEQ ID no: 4).

[illegible]

13

GENERAL DESCRIPTION OF INVENTION

As described above, the present invention, in general, relates to protection of hosts against disease caused by infection by paramyxovirus by DNA immunization using DNA vectors. In particular, the invention is concerned with protection of hosts against disease caused by infection by respiratory syncytial virus (RSV), although not specifically limited thereto. The description which follows refers specifically to employing DNA sequences encoding RSV F or G protein and fragments thereof which generate antibodies which specifically react with RSV F or G protein.

In this application, the terms "RSV F protein" and "RSV G protein" are used to define a full-length RSV F or G protein, including proteins having variations in their amino acid sequences including those naturally occurring in various strain of RSV and those introduced by PCR amplification of the encoding gene while retaining the immunogenic properties, a secreted form of the RSV F or G protein lacking a transmembrane anchor and cytoplasmic tail, as well as fragments capable of generating antibodies which specifically react with RSV F or G protein and functional analogs. In this application, a first protein is a "functional analog" of a second protein if the first protein is immunologically related to and/or has the same function as the second protein. The functional analog may be, for example, a fragment of the protein or a substitution, addition or deletion mutant thereof.

A vector is constructed to contain a first DNA sequence which is complementary to at least part of an

00190246-11398
06ET1" 94206T60

14

alphavirus RNA genome, specifically Semliki Forest virus, and having the complement of complete alphavirus RNA genome replication regions to permit replication in vivo. A second DNA sequence encoding the RSV F or G protein is inserted into a region of the first DNA sequence which is non-essential for replication. The first and second DNA sequences are under transcriptional control of a promoter to permit expression of the RSV protein in a host immunized with the vector.

10 The promoter sequence may be the immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 36. Any other convenient promoter may be used, including constitutive promoters, such as, Rous Sarcoma Virus LTRs, and inducible promoters, such as
15 metallothionine promoter, and tissue specific promoters.

The recombinant vector may include a third nucleotide sequence located adjacent the alphavirus sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed in vivo in a host.
20 Such enhancement may be provided by increased in vivo expression, for example, by increased mRNA stability, enhanced transcription and/or translation. This additional sequence preferably is located between the promoter sequence and the alphavirus sequence.

25 This enhancement sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing during transcription so that substantially all transcribed mRNA is intact alphavirus RNA encoding a gene of interest, for example, an RSV F protein. Specifically, rabbit β -globin Intron II sequence may provide such splice sites,
30 as also described in ref. 37.

09190246-11398
BGETT-94206160

15

Additional enhancement may be obtained by, including an additional DNA sequence between the promoter and the enhancer sequence. Such additional DNA sequence may comprise the immediate early
5 cytomegalovirus Intron A sequence.

The vectors provided herein, when administered to an animal, effect in vivo RSV F protein expression, as demonstrated by an antibody response in the animal to which it is administered and the conferring of
10 protection. As may be seen from the results detailed in the Examples below, the DNA vectors produced a high anti-F IgG antibody titre and confer protection.

In comparison to the vectors described in the aforementioned U.S. Patent Application nos.08/476,397
15 and 08/896,500, the vectors described herein provide a protective immune response using a lower dose and less time. In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/923,558, 08/896,550 and 08/476,397 using native RSV F, the
20 vectors described herein produce protective immune response in the absence of pretreatment of the animal model with cardiotoxin, a material known to increase the uptake of DNA and enhance the immune response.

The vector provided herein may also comprise a
25 fourth nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent, such as cytokine. Such vector may contain said fourth nucleotide sequence in a chimeric or a bicistronic structure. Alternatively,
30 vectors containing the fourth nucleotide sequence may be

09190245-111398
86ETT 94206T60

16

separately constructed and coadministered to a host, with the DNA vector provided herein.

In addition, there may be provided at the 3'-end of the Simliki Forest virus segment, a hepatitis delta virus ribosyme sequence to ensure proper *in vivo* cleavage at the 3'-end of the Simliki Forest virus sequence. Any other convenient sequence may be employed to achieve this effect.

It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.

1. Vaccine Preparation and Use

Immunogenic compositions, suitable to be used as vaccines, may be prepared from the RSV F or RSV G genes and other paramyxovirus genes and vectors as disclosed herein. The vaccine elicits an immune response in a subject which includes the production of anti-F or anti-G antibodies. Immunogenic compositions, including vaccines, containing the DNA vector may be prepared as injectables, in physiologically-acceptable liquid solutions or emulsions for polynucleotide administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 93/24640, ref. 38) or the DNA vector may be associated with an adjuvant, as described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with

09190246-11398
SECRET

17

polyanions such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. Published PCT application WO 94/27435 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.

Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable time-release particles. Thus, U.S. Patent 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moléculaires (BVSM). The particulate carriers are intended to transport a variety of molecules having biological activity in one of the layers thereof.

U.S. Patent 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50 poly (DL-lactide-co-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co-glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8-hydroxybutyric acid), and polyanhydrides.

09190246-111398

18

Published PCT application WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosa. The delivery vehicle may additionally contain an absorption enhancer.

The RSV F or G genes and vectors may be mixed with pharmaceutically acceptable excipients which are compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site with a local anaesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients,

09190246-111398

19

such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV F protein and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1 µg to about 1 mg of the RSV F or G genes and vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

In particular embodiments of the present invention, the vector comprising a first nucleotide sequence

09190246-111398

20

encoding an F or G protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.

5 The DNA vectors may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 39) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH
10 antibodies in the mice, while Furth et al. (ref. 40) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.

2. Immunoassays

15 The RSV F or G genes and vectors of the present invention are useful as immunogens for the generation of anti-F or anti-G antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art. In ELISA assays, the
20 vector first is administered to a host to generate antibodies specific to the RSV F or G protein or other paramyxovirus protein. These RSV F- or G-specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies,
25 such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed antibodies, a nonspecific protein such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample may
30 be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the

09190246 11396
BETTT 94206T60

21

immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound RSV F specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.

Biological Deposits

Certain vectors that contain the gene encoding RSV F protein and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, VA 20110-2209, U.S.A., pursuant to the Budapest Treaty and prior to the filing of this application.

Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed

06E111" 94206160

22

at that time. Non-viable deposits will be replaced. The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent or similar plasmids that encode similar or equivalent antigens as described in this application are within the scope of this invention.

Deposit Summary

10	<u>Plasmid</u>	<u>ATCC Designation</u>	<u>Date Deposited</u>
	pMP37	97905	Feb. 27, 1997
	pMP42		

EXAMPLES

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

Methods of molecular genetics, protein biochemistry and immunology used but not explicitly described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

30

09190245-11393
SECRET

23

EXAMPLE 1

This Example describes a scheme for construction of a Semliki Forest Virus (SFV) DNA expression vector containing a truncated RSV F gene as outlined in Figures 1A to 1B.

Plasmid VR1012 was restricted with PstI and then made blunt-ended with T4 DNA polymerase. The β -globin Intron II was excised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the nucleotide sequence:

TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT
CCTGCCACCTCCGCTACGCGAGAGATTAACCAACCCACGATGGCCGCCAAAGT
GCATGTTGATATTGAGGCTGACAGCCCATTTCATCAAGTCTTTGCAGAAGGCA
TTTCCGTCGTTTCGAGGTGGAGTCATTGCAGGTCACACCAAATGACCATGCAA
ATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from
pSFVI with primers SAL-SFV having the nucleotide
sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:
5) and ECO-SFV having the nucleotide sequence 5'-
TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The
resulting plasmid pMP38 was then restricted with EcoRV
and BamHI and then dephosphorylated. Plasmid pSFV1
link (see copending application no. _____ (b/o
1038-766)) was then restricted with SpeI and ligated to
the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and
3). The ligation reaction was then restricted with
EcoRV to release most of the SFV-RSVF plus ribozyme
fragment. This fragment was then ligated to
EcoRV/BamHI restricted pMP38 to produce pMP41.

24

Example 2

This Example describes an alternative scheme for constructing plasmid pMp44 as outlined in Figure 2.

Plasmid VR1012 was restricted with PstI and then
5 made blunt-ended with T4 DNA polymerase. The β -globin Intron II was excised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the
10 nucleotide sequence:

TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT
CCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCAAAGT
GCATGTTGATATTGAGGCTGACAGCCCATTTCATCAAGTCTTTGCAGAAGGCA
TTTCCGTCGTTTCGAGGTGGAGTCATTGCAGGTCACACCAAATGACCATGCAA
15 ATGCCAGAGCATTTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from
pSFVI with primers SAL-SFV having the nucleotide
sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:
5) and ECO-SFV having the nucleotide sequence 5'-
20 TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The
resulting plasmid pMP38 was then restricted with EcoRV
and BamHI and then dephosphorylated. Plasmid pSFV1
link (see copending application no. _____ (b/o
1038-766)) was then restricted with SpeI and ligated to
25 the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and
3).

The ligation reaction product was then restricted
with EcoRV to release the SFV replicon plus the
ribozyme having the nucleotide sequence as outlines in
30 Figures 6A to 6C. This fragment was then ligated to
the EcoRV/BamHI restricted pMP38 to produce pMP42. The

09190246-111398

25

RSV F gene fragment was released from pMP37 by restriction with BamHI, and this fragment was ligated into the BamHI site of pMP42 to produce pMP44. The nucleotide sequence of pMP44 is shown in Figures 3A to 3E.

EXAMPLE 3

This Example describes the immunization of mice with pMP44 and the immunogenicity results obtained.

BALB/C mice were immunized with plasmid pMP44 by the intramuscular (i.m.) route. The anterior tibialis muscles of six BALB/C mice were bilaterally injected with 2 x 100 μ g of plasmid pMP44. This amount is equivalent to approximately 94 μ g of a conventional vector, based on copy number. These mice were boosted in an identical manner 4 weeks later. The control group was immunized with 2 x 25 μ g of SFV-RSV F RNA as described in my aforementioned United States Application No. 08/923,558, except that the muscles were not pre-treated with cardiotoxin. The immunization protocol is set forth in the following Table I:

Table 1 Immunization protocol

Group	Prime	Route of Inoculation	Boost	Route of Inoculation
25	1 SFV-RSVF RNA ¹	Intramuscular	SFV-RSVF RNA ¹	Intramuscular
	2 pMP44 DNA ²	Intramuscular	pMP44DNA ²	Intramuscular

Mice were inoculated with:

1. 25 μ g of RNA was injected into each hind leg muscle in 50 μ L of PBS
2. 100 μ g of DNA was injected into each hind leg muscle in 50 μ L of PBS

26

Sera was obtained from the mice at 4 and 6 weeks. Anti-RSV F antibody titres (IgG) in these sera were determined by enzyme-linked immunosorbent assay (ELISA), as described in Example 3.

5 The anti-RSV F IgG antibody response in the sera of the BALB/C mice are summarized in Figure 4. The mice immunized with the DNA construct, pMP44, had higher anti-F titres than the mice immunized with the SFV-RSV F RNA.

10 Two weeks after the second immunization, mice were challenged intranasally with 10^6 plaque forming units (pfu) of the A1 strain of RSV (BG-4A). Animals were sacrificed 4 days later. Lungs were aseptically removed, weighed, and homogenized in 2 mL of complete
15 culture medium. The virus titre in lung homogenates was determined in duplicate using vero cells, as previously described (ref. 41).

As seen in Table 2 below, immunization of mice with pMP44 DNA protected mice (5/6) against live RSV
20 challenge, in contrast to the lack of protection when immunization with SFV-RSV F RNA was effected. This result contrasts with the complete protection which is obtained using SFV-RSV F RNA as described in U.S. Patent Application Nos. 08/923,558, 08/476,397 and
25 08/896,500 where the results show protection after pretreatment with cardiotoxin.

Table 2

Group	Immunogen		Mean Virus Lung Titre	
	Prime	Boost	(log10/g.s.d)	% Protection
30				
1	SFV-RSVF RNA	SFV-RSVF RNA	4.26	0
2	pMP44 DNA	pMP44DNA	2.12*	83

27

* Limit of detection = 1.8

EXAMPLE 4

This Example describes the determination of anti-
5 RSV F antibody titres.

Nunc-MaxiSorp plate wells were coated overnight at
room temperature with 2.5 ng of immunoaffinity-purified
RSV F protein diluted in 0.05M carbonate-bicarbonate
10 buffer, pH 9.6. Wells were blocked for non-specific
binding by adding 0.1% BSA in PBS for 30 min. at room
temperature, followed by two washes in a washing buffer
of 0.1% BSA in PBS + 0.1% Tween 20. Serial two or
four-fold dilutions of mouse serum was added to the
wells. After a one hour incubation at room
15 temperature, plates were washed five times with washing
buffer, and horseradish peroxidase (HRP) labeled
conjugate was added at the appropriate optimal dilution
in washing buffer. The total IgG assay used F(ab')₂
goat antimouse IgG (H+L specific)- HRP from Jackson
20 Immuno Research Laboratory Inc. (Baltimore, MD, USA).
Sheep anti-mouse IgG1-HRP from Serotec (Toronto,
Ontario, Canada) was used in the IgG1 assay and goat
anti-mouse IgG2a from Caltag Laboratories (San
Francisco, CA, USA) was used in the IgG2a assay.
25 Following one hour incubation at room temperature, the
plates were washed five times with washing buffer, and
hydrogen peroxide (substrate) in the presence of
tetramethylbenzidine was added. The reaction was
stopped by adding 2 M sulfuric acid. The colour was
30 read in a Multiscan Titertek plate reader at an optical
density (OD) of 450 nm. The titre was taken as the
reciprocal of the last dilution at which the OD was

09190245 111398
SECRET

28

approximately double. This OD must be greater than the negative control of the assay at the starting dilution. The pre-immune serum of each animal was used as the negative control.

5

SUMMARY OF THE DISCLOSURE

In summary of this disclosure, the present invention provides certain novel alphavirus derived DNA vectors containing genes encoding RSV F or RSV G proteins, or other paramyxovirus proteins, methods of immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.

00190246-111398
SECRET-912067ED

29

REFERENCES

1. McIntosh K. and Chanock R.M. in Fields B.N. and Knipe D.M. (eds). Virology. Raven Press, New York, 1990, pp.1045-1072.
5
2. Murphy B.R., Hall S.L., Kulkarni A.B., Crowe J.E., Collins P.L., Connors M., Karron R.A. and Chanock R.M., Virus Res 32, 13-36, 1994.
10
3. Osterweil D. and Norman D., Am Geriatr Soc 36, 659-662, 1990.
4. Agius G., Dindinand G., Biggar R.J., Peyre R., Vaillant V., Ranger S., Poupet J.Y., Cisse M.F. and Casters M., J Med Virol 30, 117-127, 1990.
15
5. Katz S.L. in New vaccine development establishing priorities Vol 1. National Academic Press, Washington, 1985, pp. 3974 09.
20
6. Wertz G.W. and Sullender W.M., Biotechnology 20, 151-176, 1992 .
7. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M. and Meiklejohn G., Am J Epidemiol 89, 449-463, 1969.
25
8. Chin J., Magoffin R.L., Shearer I.A., Schieble J.H. and Lennette E.H., Am J Epidemiol 89, 449-463, 1969.
30
9. Belshe R.B., Van Voris L.P. and Mufson M.A., J Infect Dis 145, 311-319, 1982.
35
10. Kim R.M., Arrobio J.O., Pyles G., Brandt C.D., Camargo E., Chanock R.M. and Parrott R.H., Pediatrics 48, 745-755, 1971.
11. Gruber C. and Levine S., J Gen Virol 64, 825-832, 1983.
40
12. Olmstead R.A., Elango N. and Prince G.A., Proc Natl Acad Sci USA 83, 7462-7466, 1991.
45

09190246-11395
062211-94206160

30

13. Parrington M., Cockle S., Wyde P., Du R.-P., Snell E., Yan W.-Y., Wang Q., Gisonni L., Sanhueza S., Ewasyshyn M. and Klein M., Virus Genes 14, 65-74, 1997
- 5 14. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M. and Meiklejohn, G. (1969) Am. J. Epidemiol. 89 (4), 435-448.
- 10 15. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) Am. J. Epidemiol. 89 (4), 449-463.
- 15 16. Jensen, K.E., Peeler, B.E. and Dulworth, W.G. (1962) J. Immunol. 89, 216-226.
- 20 17. Murphy, B.R., Prince, G.A., Collins, P.L., Van Wyke-Coelingh, K., Olmsted, R.A., Spriggs, M.K., Parrott, R.H., Kim, H.-Y., Brandt, C.D. and Chanock, R.M. (1988) Vir. Res. 11, 1-15.
- 25 18. Hall, S.L., Sarris, C.M., Tierney, E.L., London, W.T., and Murphy, B.R. (1993) J. Infect. Dis. 167, 958-962.
- 30 19. Belshe, R.B., Karron, R.A., Newman, F.K., Anderson, E.L., Nugent, S.L., Steinhoff, M., Clements, M.L., Wilson, M.H., Hall, S.L., Tierney, E.L. and Murphy, B.R. (1992) J. Clin. Microbiol. 30 (8), 2064-2070.
- 35 20. Hall, S.L., Stokes, A., Tierney, E.L., London, W.T., Belshe, R.B., Newman, F.C. and Murphy, B.R. (1992) Vir. Res. 22, 173-184.
- 40 21. Van Wyke Coelingh, K.L., Winter, C.C., Tierney, E.L., London, W.T. and Murphy, B.R. (1988) J. Infect. Dis. 157 (4), 655-662.
22. Ray, R., Novak, M., Duncan, J.D., Matsuoka, Y. and Compans, R.W. (1993) J. Infect. Dis. 167, 752-755.
23. Ray, R., Brown, V.E. and Compans, R.W. (1985) J. Infect. Dis. 152 (6), 1219-1230.
- 45 24. Ray, R. and Compans, R.W. (1987) J. Gen. Virol. 68, 409-418.

00190246-11398

31

25. Ray, R., Glaze, B.J., Moldoveanu, Z. and Compans, R.W. (1988) J. Infect. Dis. 157 (4), 648-654.
- 5 26. Ray, R., Matsuoka, Y., Burnett, T.L., Glaze, B.J. and Compans, R.W. (1990) J. Infect. Dis. 162, 746-749.
- 10 27. Ray, R., Glaze, B.J. and Compans, R.W. (1988) J. Virol. 62 (3), 783-787.
28. Ewasyshyn, M., Caplan, B., Bonneau A.-M., Scollard, N., Graham, S., Usman, S. and Klein, M. (1992) Vaccine 10 (6), 412-420.
- 15 29. Ambrose, M.W., Wyde, P.R., Ewasyshyn, M., Bonneau, A.-M., Caplan, B., Meyer, H.L. and Klein, M. (1991) Vaccine 9, 505-511.
- 20 30. Kasel, J.A., Frank, A.L., Keitel, W.H., Taber, L.H., Glezen W.P. J. Virol. 1984; 52:828-32.
31. Lehman, D.J., Roof, L.L., Brideau, R.J., Aeed, P.A., Thomsen, D.R., Elhammer, A.P., Wathen, M.W. and Homa, F.L. (1993) J. Gen. Virol. 74, 459-469.
- 25 32. Brideau, R.J., Oien, N.L., Lehman, D.J., Homa, F.L. and Wathen, M.W. (1993) J. Gen. Virol. 74, 471-477.
- 30 33. Ebata, S.N., Prevec, L., Graham, F.L. and Dimock, K. (1992) Vir. Res. 24, 21-33.
34. Hall, S.L., Murphy, B.R. and Van Wyke Coelingh, K.L. (1991) Vaccine 9, 659-667.
- 35 35. Strauss E.G. and Strauss J.H., in Schlesinger S.S. and Schlesinger M.i. (eds). The Togaviridae and Flaviviridae. Plenum Press, New York, 1986, pp.35-90.
- 40 36. Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., Nucl. Acids. Res. 1991, 19: 3979-3986.
- 45 37. Breathnack, R. and Harris, B.A., Nucl. Acids Res. 1983, 11: 7119-7136

00190246 11390

38. Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 90:
11307-11311.
- 5 39. Tang et al., Nature 1992, 356: 152-154
40. Furth et al. Analytical Biochemistry, 1992, 205:
365-368
- 10 41. Prince, G.A. et al, Am. J. Pathol. 93, 771 to 790,
1978.

09100246 111398
060711 04206160

Figure 4 Construction of pMP44

1/16




Fig. 4a 10a

00190246 11398

2/16





Fig 1B

00190246-113380



+ Acc II fragments
from pM137

↓

Ligate

↓

Fig 1c

00190246 1139

4/16




FIG 10

0019046 94206T60

5/16



Figure-1 Construction of pMP44

fig. 24

09190246 111398

6/1/98



09190246 111398

7/16

Figure 2 Nucleotide sequence of plasmid pMP44

tcgcgcgttt cggatgatgac ggtgaaaacc tctgacacat gcagctcccg gagacgggtca 60
 cagcttgtct gtaagoggat gccggggagca gacaagcccg tcagggcgcg tcagcgggtg 120
 ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc 180
 accatatgcg gtgtgaaata ccgcacagat gcgttaaggag aaataaccgc atcagattgg 240
 ctattggcca ttgcatacgt tgtatccata tcataatfatg tacatttata ttggctcatg 300
 tccaacatta ccgccatggt gacattgatt attgactagt tattaatagt aatcaattac 360
 ggggtcatta gttcatagcc catatatgga gttccggcgt acataactta cggtaaatgg 420
 ccgcctggc tgaccgcccc acgacccccg cccattgacg tcaataatga cgtatgttcc 480
 catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac 540
 tgcccacttg ccagtacatc aagtgtatca tatgccaatg acgcccccta ttgacgtcaa 600
 tgacggtaaa tggcccgctt ggcattatgc ccagtacatg accttatggg actttccctac 660
 ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatggcgt tttggcagta 720
 catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga 780
 cgtcaatggg agtttgtttt ggcacccaaa tcaacggggac tttccaaat gtctaacaaa 840
 ctccgccccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag 900
 agctcgttta gtgaaccgtc agatcgccgt gagacgcaat ccaogctgtt ttgacctcca 960
 tagaagacac cgggacccgat ccagcctccg cggccgggaa cgggtgcattg gaacgcggat 1020
 tccccgtgcc aagagtgcag taagtaccgc ctatagactc tataggcaca cccctttggc 1080
 tcttatgcct gctatactgt ttttggcttg gggcctatac acccccgctt ccttatgtca 1140
 taggtatagg tatagcttag cctataagtg tgggttattg accattattg accactcccc 1200
 tattgggtgac gatactttcc attactaatc cataacatgg ctotttggca caactatctc 1260
 tattggctat atgccaatac tctgtccttc agagactgac acggactctg tatttttaca 1320
 ggaatggggtc oaatattatta tttaacaatt cacatataca acaacgcctg cccccgtgcc 1380
 cgcagttttt attaaacata guctgggac tccacgcgaa tctcgggtac gtgttccgga 1440
 catgggctct tctccggtag cggcggagtc tccacatccg agccctggtc coactgctcc 1500
 agcggctcat ggtcgtctgg cagctccttg ctccctaacag tggaggccag acttaggcac 1560
 agcacaatgc ccaccaccac cagtgtgccg cacaagggcg tggcggtagg gtatgtgtct 1620
 gaaaatgagc gtggagattg ggctcgcacg gctgacgcag atggaagact taaggcagcg 1680
 gcagaagaag atgcaggcag ctgagttgtt gtattctgat aagagtcaga ggtaactccc 1740
 gttgcgggtg tgttaacggt ggagggcagt gtagtctgag cagtaoctgt tgctgcccg 1800
 ccgcgcccca gacataatag ctgacagact aacagactgt tcccttccat gggtcttttc 1860
 cgatcctgag aacttoaggg tgagtttggg gacccctgat tgttctttct ttttcgctat 1920
 tgtaaaattc atgttatatg gagggggcaa agttttcagg gtgttgttta gaatgggaag 1980
 atgtcccttg tatcccatg gacccctcat ataattttgt ttctttcact ttctactctg 2040
 ttgacaacca ttgtctcttc ttttttctt cacttttgtt tatttgtag attgtaagta 2100
 tagcttgcct ttgtaacgaa tttttaaatt tcagggtata ttatattgta cttcagcaca 2160
 ctttctctaa tcactttttt ttcaaggcaa ataaggtaga atatttctgc atataaattc 2220
 gtttttagaa acaattgtta taattaaatg aaacaactac atatttctgc atataaattc 2280
 tggctggcgt ggaaatatcc ctattggtag gatatacact atcctggtea atataaattc 2340
 tttctcttta tggttacaat gatatacact gtttgagatg aggtataaat actctgagtc 2400
 caaacggggc cctctgtcta accatgttca tgccttcttc ttttctctac agctcctggg 2460
 caacgtgctg gttattgtgc tgtctcatca ttttggcaaa gaattgtaat acgactcact 2520
 ataggggcga atgtcacctg cgtcgacatg gggatgtgt gacatacacg acgccaagag 2580
 attttgttcc agctcctgac acctccgcta cgcagagat taaccaacca cgtatggcgc 2640
 caaagtgcct gttgatattg aggtgcacg cccattcatc aagtctttgc agaaggcatt 2700
 tccgtccttc gaggtggagt cattgcaggt gaccccaat gaccatgcaa atgccagagc 2760
 attttcgcac ctggctacca aattgatcga gcaggagact gacaaagaca cactcatctt 2820
 ggatatcggc agtgccgctt ccaggagaat gatgtctacg cacaatatcc actgcgtatg 2880
 ccttatgcgc agcgcagaag accccgaaag gctcgatagc tacgcaagaa aactggcagc 2940
 ggctccggg aaggtgctgg atagagagat cgcaggaaaa atcacccgac tcagaccctg 3000
 catggctacg ccagacgctg aatctcctac cttttgctg catacagacg tcacgtgtcg 3060
 tacggcagcc gaagtggcgc tataccagga cgtgtatgct gtaactgcac caacatcgct 3120
 gtaccatcag gcgatgaaag gtgtcagaac ggcgtattgg attgggtttg acaccacccc 3180
 gtttatgttt gacgcgctag caggcgcgta tccaacctac gccacaaact gggccgacga 3240

8/16

0311397 "94206160"

```

gcaggtgtta caggccagga acataggact gtgtgcagca tccttgactg agggagact 3300
cggcaactg tccattctcc gcaagaagca attgaaacct tgcgacacag tcatgttctc 3360
ggtaggatct acattgtaca ctgagagcag aaagctactg agggagctggc acttaccttc 3420
cgtattccac ctgaagggtt aaacatcctt tacctgtagg tgcgatacca tegtatcatg 3480
tgaagggtag gtagttaaga aaatcactat gtgccccggc ctgtacggta aaacggtagg 3540
gtacgccgtg acgtatcacg cggagggatt cctagtgtgc aagaccacag acactgtcaa 3600
aggagaaaga gtctcattcc ctgtatgcac ctacgtcccc tcaacctctt gtgatcaaat 3660
gactggcata ctagcgaccg acgtcacacc ggaggacgca cagaagttgt tagtgggatt 3720
gaatcagagg atagtgtgga acggaagaac acagcgaaac actaacacga tgaagaacta 3780
tctgtctccg attgtggcgg tcgcatttag caagtgggcg agggaaataca aggcagacct 3840
tgatgatgaa aaacctctgg gtgtccgaga gagggtcactt acttgctgct gcttgtgggc 3900
atttaaaacg aggaagatgc acacctgtta ccaagaaacca gacacccaga caatagttaa 3960
ggtgccttca gagtttaact cgttcgtcat cccgagccta tggctctacg gcctcgcaat 4020
cccagtcaga tcacgcatta agatgctttt ggccaagaag accaagcgag agttaatacc 4080
tgttctcgac gcgtcgtcag ccagggatgc tgaacaagag gagaaggaga ggttggaggg 4140
cgagctgact agagaagcct taccacctct cgtccccatc gcgcccggcg agacgggagt 4200
cgtcgacgtc gacgttgaag aactagagta tcacgcaggt gcaggggtcg tggaaacacc 4260
tcgcagcgcg tgaaggta cgcacagacc gacgcagcta ctactaggaa attacgtagt 4320
tctgtccccg cagaccgtgc tcaagagctc caagttggcc cccgtgcacc ctctagcaga 4380
gcaggtgaaa ataactaacg ataacgggag ggccggcggt taccaggtcg accgtatga 4440
cggcaggggt ctactacct actatgggtg acaacgaaag ggagttcgtc cctgagtttc 4500
cgagagcgcc actatgggtg ggacccgtcg tgaacaccca cgaggagaaac tacyagaag 4560
tgccgttcac aagaactgac gccaggtacg tgttcgacgt agataaaaaa tgctgctca 4620
agaactgac agcgtcggtg ttggtgttgg cgtcggcacc atataagact acagttagtag 4680
cgaagggctg cgaagggctg tcaggaagtc cgttcocatg aatttcgcta 4740
ggttccggga caccagcgcc aaganggaga actgcccagga aatagttaac gacgtgaaga 4800
caccagcgcc gaaggggaca agtagggaaa acagtgactc catcctgcta aacgggtgtc 4860
ggacatccta tatgtggacg aggtcttcgc ttgocattcc ggtactctgc 4920
tgctcttgtt aaacctcgga gcaagtggt gttatgogga gaccccaagc 4980
cttcaatatg atgcagctta aggtgaactt caaccacaac atctgcactg 5040
taaaagtata tccagacgtt gcaacgctcc ccaacccgtg ggtacatctg 5100
cggagggcaag atgcgcacga ccaacccgtg gacacgaagt catgacagca 5160
acagaccag cccaagccag gagacatctg taaggcagaa ggtgaatgaa 5220
gctgaggttg gactacogtg gacacgaagt catgacagca ggtgaatgaa 5280
ccgcaaaagg gtatacgcgg gtgaatgtac tgctgacggc cactgaggat 5340
gtcggagcac ggcggcgcat cccgtggatta aggtcctatc aaacattcca cagggttaact 5400
ggcggcgcat attggaagaa tggcaagaag aacacgacaa aataatgaag gtgattgaag 5460
gootgtggac gcgttcacga acaaagcgaa cgtgtgttgg gcgaaaagcc 5520
cctggacact gcgggaatca gattnacagc agaggagtg ggccctgaa 5580
taaggaggac agagottact ctccagtggt gcoctgtttc gatgtatgga 5640
tggagttgac ctggacagtg gctgtgttcc ccttccgtga ggggcagtg 5700
caaccactgg gataaacagac ctggttggag ggtgtgttcc tctgctggac 5760
caggctggaa gotagacata aacogcttcc tggctgagta caagacggtt 5820
tatcgagaa agaaaaatcc aacogcttcc tggctgagta cctgctgggt 5880
caggctgccc cagccoctgg ggtaccacgt ggttgtcacc cgtgaatgtc 5940
gctggtcaat aaagtaagag aggttgcacc oggtgacgc gcagtggtc 6000
gcctcgacgc aggttcaact ttaggactgc accactacca tacgactgct 6060
cgacctaggt ttaggactgc accactacca tacgactgct aacaccggc 6120
tcacacggaa ttcagaatcc accactacca tacgactgct aacaccggc 6180
gatgcttggg ggagatgcgc ggaagccgt cgtttcctcc ttaagcagaa 6240
cggatagcgc gataaaatca ggaagccgt cgtttcctcc ttaagcagaa 6300
tgcaagagtg ttgcgccggg attgtgtcac gaagtgttct tgctgttctc 6360
caactttgac aacggaaaga gacccctcac gctacaccag atgaatacca 6420
cgtgtatgcc ggagaagcca tgcacacggc cgggtgtgca ccatcctaca 6480
gagttaagag 6540
gagttaagag 6600
gagttaagag 6660

```

9/16

09190246 11399

```

agcagacata gccacgtgca cagaagcggc tgtggttaac gcagctaacg ccogtggaa 6720
tgtaggggat ggcgtatgca gggccgtggc gaagaaatgg ccgtcagcct ttaagggagc 6780
agcaacacca gtgggcacaa ttaaaacagt catgtgcggc tcgtaccccg tcattccacgc 6840
tgtagcgoot aatctctctg ccacgactga agcggaaagg gaccgcgaat tggccgctgt 6900
ctacccggca gtggccggcg aagtaaacag actgtcactg agcagcgtag ccattcccgt 6960
gctgtccaca gtagtgttca gggcggaag agataggctg cagcaatccc tcaacctct 7020
attcacagca atggacggca cggacgctga cgtgaccatc tactgcagag acaaaagttg 7080
ggagaagaaa atccagggaag ccattgacat gaggacggct gtggagtgtc tcaatgatga 7140
cgtggagctg accacagact tggtagagat gcacccggac agcagootgg tgggtcgtaa 7200
gggtacagt accactgacg ggtcgtctga ctctactttt gaaggtacga aattcaacca 7260
ggctgctatt gatattggcag agatactgac gttgtggccc agactgcaag aggcacacga 7320
acagatatgc ctatacggcg tgggcgaac aatggacaa atcagatcca aatgtccggt 7380
gaacgattcc gattcatcaa cactcccag gacagtgcct tgctgtgcc gctacgcaat 7440
gacagcagaa cggatogccc gocttaggtc acaccaagtt aaaagcatgg tggtttgctc 7500
atcttttccc ctccggaaat accatgtaga tgggtgcag aaggtaaagt gcgagaaggt 7560
tctctgttcc accccgacgg taccttcagt gtttagtcgg cggaaagtat ccgcatctac 7620
gacggaccaa tcagatcggt cgttacgagg gtttgacttg gactggacca cogactcgtc 7680
ttccactgcc agcgatacca tgtcgtacc cagtttgacg tcgtgtgaca tcgactcgat 7740
ctacgagcca atggctccca tagtagtgac ggctgacgta caccctgaac ccgcaggcat 7800
cgcggacccc ggcgcagatg tgcacctga agccgcagac catgtggacc tcgagaaccc 7860
gattccccc cccgcggcga agagagctga atacctgcc tcccgccggg cggagcgacc 7920
ggtgccggcg ccgagaaagc cgaagcctgc ccaaggaact gcgtttagga acaagctgcc 7980
tttgacgttc ggcgactttg acgagcacga ggtcgtatgc ttggcctccg ggattacttt 8040
cggagacttc gacgacgtcc tgcgactagg ccgcgcgggt gcataatatt tctcctcgga 8100
cactggcagc ggacatttac aacaaaatc cgttaggcag cacaatctcc agtgcgcaca 8160
actggatgcg gtccaggagg agaaatgta cccgccaaa ttggatactg agagggagaa 8220
gctgttgctg ctgaaatgct agatgcaccc atcggaggct aataagagtc gataccagtc 8280
tcgcaaagtg gagaacatga aagccacggt ggtggacagg ctcacatcgg gggccagatt 8340
gtacacggga gcggacgtag gcgcataacc gttcggtaac gttcggtaac ccgcgccgt 8400
gtactcccc cccgtgatcg aaagattctc aagccccgat gtagcaatcg cagcgtgcaa 8460
cgaataccta tccagaaatt acccaacagt ggcgtcgtac cagataacag atgaatacga 8520
cgcatacttg gacttggttg accggtcgga tagttgcttg gacagagcga cattctgcc 8580
ggcgaagctc cgggtgctacc cgaacatca tgcgtaccac cagccgactg tacgcagtgc 8640
cgtcccgctc ccttttcaga acacactaca gaacgtgcta ggcggccgca ccaagagaaa 8700
ctgcaaccaa acgcaaatgc gagaactacc caccatggac tcggcagtg tcaacgtgga 8760
gtgcttcga cgtctgctc gctccggaga atattgggaa gaatatgcta aacaacctat 8820
ccggataaac ctgagaaca tcactacctc ttgacccaaa ttgaaaggcc cgaagctgc 8880
tgccttgctc gctaagaccc acaacttggt tccgctgcag gaggttccca tggacagatt 8940
cacggctgac atgaaccgag atgtcaaatg cactccaggg acgaaacaca cagaggaaag 9000
acccaaagt caggtaatcc aagcagcgga gccattggcg accgcttacc tgtgcggcat 9060
ccacagggaa ttagtaagga gactaaatgc tgtgttaacg cctaacgtgc acacattgtt 9120
tgatatgtcg gccgaagact ttgacgcgat catcattcga cacttccacc caggagaccc 9180
ggttctagag acggacattg atctaggggt ggtgtcacct caaaagccag gacgactcct tggctcttac 9240
aggtttaatg atcctcgaag atctaggggt ggatcagtao ctgctggact tgatcgaggg 9300
agcctttggg gaaatatcca gctgtcacct accaactggc acgcgcttca agttcgagc 9360
tatgatgaaa tcgggcatgt ttctgacttt gtttattaac actgttttga acatcaccat 9420
agcaagcagg gtactggagc agagactcac tgactccga tctgcggcct tcatcggcga 9480
cgacaacatc gttocaggag tgatctccga gcggagaggt gcgctcgtg 9540
ggtcaacatg gaggtgaaga tcattgacgc gaaacacccc catatttttg 9600
tgggggattc atagtttttg acagcgtcac tgccgtgttt cagacccact 9660
taagcgctg ttoagtttg gtaagccgct aacagctgaa gacaagcagg acaggtttg 9720
gcgacgagca ctgagtgaag aggttagcaa agaggttccg acaggtttg 9780
ggaggtggca ctaacatcta ggtatgaggt aagggutgc aaaagtatc 9840
ggccacottg gogagggaca ttaaggcgtt taagaaattg agaggacct 9900
ctacggcggt cctagattgg tgcgttaata cagagaatto cgagtaacaa tgagttgct 9960
attataggat ccgcggcgcg gaattcgga gtcacatttt gttttgctc tggtcacaaa 10020
gcaaatgcaa ttaccacaat cctcactgca gtcacatttt gttttgctc tggtcacaaa 10080

```

10/16

atcaactgaag aattttatca atcaacatgc agtgcagtta gcaaaggcta tcttagtgct 10140
ctgagaactg gttggtatcac cagtgttata actatagaat taagtaatat caaggaaaat 10200
aagtgtaatg gaacagatgc taaggtaaaa ttgataaaac aagaattaga taantataaa 10260
aatgctgtaa cagaattgca gttgtctatg caaagcacac cagcagcaaa caatcgagcc 10320
agaagagAAC taccaagggt tatgaattat acactcaaca atgccaaaaa aacctatgta 10380
acattaaagca agaaaaggaa aagaagattt cttgggtttt tgtaggtgt tgatctgca 10440
atcgccagtg gcgttgctgt atctaagggt ctgcaactag aagggggaagt gaacaagatc 10500
aaaagtgtct tactatccac aaacaagggt gtagtcagct tatcaaatgg agttagtgtc 10560
ttaaccagca aagtgttaga cctcaaaaac tatatagata aacaattgtt acctattgtg 10620
aacaagcaaa gctgcagcat atcaaatata gaaactgtga tagagttcca acaaaagaac 10680
aacagactac tagagattac cagggaattt agtggttaatg cagggtgtaac tacacctgta 10740
agcaacttaca tgtaactaa tagtgaatta ttgtcattaa tcaatgatat gcctataaca 10800
aatgatcaga aaaagttaat gtccaacaat gttcaaatag ttagacagca agttactct 10860
atcatgtcca taataaaaga ggaagtotta gcatatgtag tacaattacc actatatggt 10920
gttatagata caccctgttg gaaactacac acatcccctc tatgtacaac caacacaaaa 10980
gaagggtcca acatctgttt aacaagaact gacagaggat ggtactgtga caatgcagga 11040
tcagtatctt tcttcccaca agctgaaaca tgtaaaagttc aatcaaatcg agtattttgt 11100
gacacaatga acagtttaac attaccaagt gaaataaatc totgcaatgt tgacatattc 11160
aaccocaaat atgattgtaa aattatgact tcaaaaacag atgtaagcag ctccgttatc 11220
acatctctag gagccattgt gtcatgctat ggcaaaaacta aatgtacagc atccaataaa 11280
aatcgtggaa tcataaagac attttctaac ggtgctgatt atgtatcaaa taaagggatg 11340
gacactgtgt ctgtaggtaa cacattatat tatgtaaata agcaagaagg taaaagtctc 11400
tatgtaaaag gtgaaccaat aataaatttc tagacccat tagtattccc ctctgatgaa 11460
tttgatgcat caatatctca agtcaacgag aagattaaac agagcctagc atttattcgt 11520
aaatccgatg aettattaca taattgaaat gctggtaaat ccaccacaaa tatcatgact 11580
tgataatgag gatccagatc cggggttaatt aattgaatta catcctaag caaaogtttt 11640
acggccggccg gtggggcccg cggccggcg ttccaggccc agcagatgca gcaactcatc agcgccgtaa 11700
tggtcccggt cgtcccogac ttccaggccc gcaactcatc gcaactcatc agcgccgtaa 11760
atgcgctgac aatgagacag aacgcaattg ctctgctag gctcccaca ccaagaaga 11820
agaagacaa ccaaccaaag ccgaaaacgc agcccaagaa gatcaacgga aaaagcagc 11880
agcaaaagaa gaaagacaag caagccgaca agaagaagaa gaaacccgga aaaagagaa 11940
gaatgtgcat gaagattgaa aatgactgta tcttcgtatg cggctagcca cagtaacgta 12000
gtgtttccag acatgtoggg caccgcacta tcattgggtg agaaaatctc ggggtggtctg 12060
ggggccttgc caatcgggoc tatcctgggt ctggttggtg tcaactgcat tgggctccg 12120
agataaggta gggtaggcaa tggcattgat atagcaagaa aattgaaaa agaaaaagtt 12180
agggtaaagca atggcatata accataactg tataacttgt aacaagcgc aacaagacct 12240
gcgcaattgg cccogtgggt cgcctcagcg aaactcgggg caactcatt tgacacatta 12300
attggcaata attggaagct tacataagct taattcgag aataattgga tttttatttt 12360
atthtgcaat tgggtttttaa tttttccaaa aaaaaaaata gcaaaataaa 12420
aaaaaaataa aaaaaaaata aaaaaaaata gcaaaataaa atggcatctc 12480
cacctctctg oggtccgaac tgggcatcgg aaggaggacg cactccact cggatggcta 12540
agggagagat ccagatctgc tgtgccttct agttgccagc catctgttgt ttgcccctcc 12600
cccgtgcctt ccttgaccct ggaagggtgoc actccactg tcctttccta ataaaatgag 12660
gaaattgcat cgcattgtct gagtaggtgt cattctattc tggggggtgg ggtggggcag 12720
gacagcaagg gggaggattg ggaagacaa agcaggcatg ctggggatgc ggtgggctct 12780
atgggtaccc aggtgctgaa gaattgacc ggttcctctc gggccagaaa gaagcaggca 12840
catccccttc tctgtgacac accctgtcca cggccctggt tcttagttcc agcccactc 12900
ataggacact catagctcag gagggtccg ccttcaatcc caccgcata agtacttga 12960
goggtctctc cctccctcat cagccaccca aaccaaactc agcctccaag agtgggaaga 13020
aattaaagca agataggcta ttaagtgcag agggagagaa aatgcctcca acatgtgag 13080
aagtaatgag agaatcata gaatttcttc cgttctctc ctactgact cgtgogctc 13140
ggtogttcgg ctggygcgag cggtatcagc tcaactcaag gcgtaatac ggttatccac 13200
agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa 13260
ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cggcccccctg acgagcatca 13320
caaaatcga cgttcaagtc agaggtggcg aaaccgaca ggaactataa gataccaggc 13380
gtttccccc cgttcaagtc tctgtgctc tctgttccg accctgccc ttaccggata 13440
cctgtccgoc tttctccctt cgggaagcgt ggogctttct catagctcac gctgtaggta 13500

A 3 D


11/16

09190246 111396

tctcagttcg	gtgtaggtcg	ttogctccaa	gtcgggctgt	gtgcacgaac	cccccgttca	13560
gccgcaccgc	tgccgcttat	ccggtaacta	togtcttgag	tccaaccggy	taagacacga	13620
cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	agagcgaggt	atgtaggcgg	13680
tgctacagag	ttcttgaaat	ggtggcctaa	ctacggctac	actagaagaa	cagtatttgg	13740
tatctgcgct	ctgctgaagc	cagttacctt	cggaaaaaga	gttggtagct	cttgatccgg	13800
caaacaaaac	accgctggta	gcggtgggtt	ttttgtttgc	aagcagcaga	ttacgcgcag	13860
aaaaaaagga	tctcaagaa	atcctttgat	cttttctacg	gggtctgacg	ctcagtggaa	13920
cgaaaactca	cgttaaggga	ttttgggtcat	gagattatca	aaaaggatct	tcacctagat	13980
cctttttaat	taaaaatgae	gttttaaatc	aactctaaagt	atatatgagt	aaacttggtc	14040
tgacagttac	caatgcttaa	tcagtgaaggc	acctatctca	gcgatctgtc	tatttcgttc	14100
atccatagtt	gcctgactcg	gggggggggg	gcgctgaggt	ctgcctcgtg	aagaagggtg	14160
tgctgactca	taccaggcct	gaatcgcccc	atcatccagc	cagaaagtga	gggagccacg	14220
gttgatgaga	gctttgttgt	aggtggacca	gttggtgatt	ttgaactttt	gctttggcac	14280
ggaacgggtc	gcgttgctgg	gaagatgcgt	gatctgatcc	ttcaactcag	caaaagttcg	14340
atatttccaa	caaaagccggc	gtcccgctca	gtcagcgtaa	tgctctgcca	gtgttacaac	14400
caattaacca	attgtgatta	gaaaaactca	tcgagcatca	aatgaaactg	caatttatte	14460
atatcaggat	tatcaatacc	atatttttga	aaaagccggt	tctgtaatga	aggagaaaac	14520
tcaccgaggc	agttoccatag	gatggcaaga	tcctgggtatc	ggtctgcgat	tcogaotcgt	14580
ccaacatcaa	tacaacctat	taatttcccc	tcgtcaaaaa	taaggttatc	aagtgaagaa	14640
tcacctagag	tgacgactga	atccggtgag	aatggcaaaa	gcttatgcat	ttctttccag	14700
acttggtcaa	caggccagcc	attacgctcg	tcatacaaat	cactcgcatc	aaccaaaccc	14760
ttattcattc	gtgattgcgc	ctgagcgaga	cgaataacgc	gatcgctgtt	aaaaggacaa	14820
ttacaaaacag	gaatcgaatg	caaccggcgc	aggaaactcg	ccagcgcatc	ascaatatatt	14880
tcacctgaat	caggatattc	ttctaatacc	tggaaatgctg	ttttcccggg	gatcgcaagt	14940
gtgagttaacc	atgcatcatc	aggagtaacg	ataaaatgct	tgatggctcg	aagaggcata	15000
aattccgtca	gccagtttag	tctgaccatc	tcattctgtaa	catcattggc	aacgctacct	15060
ttgcatgtt	tcagaaacaa	ctctggcgca	tcgggottcc	catacaatcg	atagattgtc	15120
gcacctgatt	gcccgcacatt	atcgcgagcc	catttatacc	catataaatc	agcatccatg	15180
ttggaattta	atcgcgccct	cgagcaagac	gtttcccggt	gaatatggct	cataacgttc	15240
cttgattatc	tgtttatgta	agcagacagt	tttattgttc	atgatgatat	atttttatct	15300
tgtgcaatgt	aacatcagag	attttgagac	acaaactggc	tttccccccc	ccccatttat	15360
tgaagcattt	atcaggggta	ttgtctcatg	agcggatata	tattttgaatg	tatttagaaa	15420
aataaacaan	taggggttcc	gcgcacattt	ccccgaaaag	tgccacctga	cgtctaagaa	15480
accattatta	tcattgacatt	aacctatata	aataggcgta	tcacgaggcc	ctttcgtc	15538

12/16

Figure 4. Anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after boosting



B6ETTT 94206160

[illegible]

Figure 5 Ribozyme linker for pMP42

5' CTAGCGGGTCGGCATCGCATACCTCTCGCGGTCCGACTGCGCATCCGAGGAGGACGCCAGTCCACTCGGATGGCTAAGSGAGA
3' GCCCAGCCGTACCGTAGAGGTTGAGGAGCGCCAGGCTGGACCCGTAGGCTTCTCTCGGTGCAGGTAGCCCTACCGATTCCCTCTCTAG

13/16

14/16

Figure 6SFV Eco RV-Spe I fragment ligated to ribozyme

atcggcagtg agccttccag gagaatgatg tctacgcaca aataccactg cgtatgccct 60
 atggcagcgg cagaagaccc cgaaggctc gatagctacg caaagaaact ggtagggg 120
 tcggggaagg tgctggatag agagatcgca ggaanaatca ccgacctgca gaccgtcatg 180
 5 gctacgcccag acgtggaatc tctacacctt tgcctgcata cagacgtcac gtgtcgtacg 240
 gcagccgaag tggccgtata ccaggacgtg tatgctgtac atgcaaccaac atcgtgttac 300
 catcaggcga tgaagggtgt cagaacggcg tattggattg ggtttgacac caccocgttt 360
 atgtttgacg cgtacgacgg cgcgtatcca acctacgcca caaactgggc cgcagagcag 420
 10 gtgttacagg ccagggaacat aggaactgtgt gcagcatcct tgactgaggg agactcggc 480
 aaactgtcca ttctccgcaa gaagcaattg aaaccttgcc acacagtcac gttctcggta 540
 ggtatctacat tgtaacactga gagcagaaag ctactgagga gctggcactt accctccgta 600
 ttccactgtg aaggtaaaca atcctttacc tgtagggtgg ataccatcgt atcatgtgaa 660
 gggtacgtga ttaagaaaaa cactatgtgc ccgggctgt acggtaaaaa ggtagggtac 720
 gcggtgacgt atcacgcgga gggattccta gtgtgcaga ccacagacac tgtcaaggga 780
 15 gaaagagctc cattccctgt atgcacctac gtccctcaa coactctgtg tcaaatgact 840
 ggcatactag cgaacggcgt cacaacggag gaagcacaga agttgttagt gggattgaat 900
 cagaggatag ttgtgaaagg aagaacacag cgaacacta aacagatgaa gaactatctg 960
 20 ctccgatttg tggcgtcggc atttagcaag tggcogaggg aatacaaggc agactctgat 1020
 gatgaaaaac ctctgggtgt ccgagagagg tcacttaact gctgctggtt gtgggcattt 1080
 aaaaacgagg aatgtaacac catgtacaag aaaccagaca ccacagcaat agtgaaggtg 1140
 ccttcagagt ttaactcgtt cgtcatcccg agcctatggt ctacaggcct cgaatccca 1200
 25 gtcagatcac gcattaaagt gcttttggcc aagaagacca agcagaggtt aatacctgtt 1260
 ctgacgcggt cgtacggcag ggatgctgaa caagaggaga aggaaggtt ggaaggccag 1320
 ctgactagag aagccttacc acccctcgtc ccctacggc cggcggagac gggagtcgtc 1380
 gaogtcgacg ttgaagaact agagtatcac gcaggtgcag gggtcgtgga aacacctcgc 1440
 agcgcgttga aagtcacccg acagccgaac gagctactac taggaattta cgtagttctg 1500
 30 tccccgcaga cgtgtctcaa gagctccaa ggggagggcc ggggttacc aggtcgacgg atatgacggc 1560
 gtgaaaataa taacacataa cgggagggcc atcggccatt ccggtccctg agtttcagc tttgagcgag 1620
 agcgcacta tgggtgtacaa cgaaggggag ttctgtcaaa ggaactata ccatattgac 1680
 35 gttcaccggc cgtcgtgtga caccgacgag gagaactacg agaaagtac agdtgaaaga 1800
 actgaacggc agtacgtgtt agtacgtgat aaaaaatgct gcgtcaagag agagggaagc 1860
 togggtttgg tgttgggtgg agagotaaac aacccccgt tccatgaatt cgcctacgaa 1920
 gggctgaaga tcaggccgtc ggcaacctat aagactacag tagtaggagt ctttgggggt 1980
 40 ccgggatcag gcaagtctgc tattattaag agcctcgtga ccaaacacga tctgggtcac 2040
 agcggcaaga aggaagaact ccaggaaata gttaacgacg tgaagaagca ccgcggaag 2100
 gggacaagta gggaaaaacg tgactccatc ctgtcaaacg ggtgtcgtcg tgcgtggac 2160
 atcctatatg tggacgagggc tttcgtttgc cattccggtg ctotgctggc cctaattgct 2220
 45 cttgttaaac ctgggagcaa agtgggtgtt tgcggagacc ccaagcaatg cggattcttc 2280
 aatattgatg agcttaaggt gaacttcaac cacaacatct gcactgaagt atgtcataaa 2340
 agtatatcca gacgttgcaa ccogtgcac acggccatcg tgtctacgtt gcactacgga 2400
 ggaagatgc gacgaccaa cccgtgcac caatgcttcc gatgtggg ccaaggacag 2460
 50 accaagccca agccaggaga catcgtgtta cgaagtcatg acagcagcag catctcaggy cctcaccgco 2520
 cagttggaat accgtggaca cgaagtcatg gcagaaggtg aatgaaatc ccttgtatgc cctgogtgc 2580
 45 aaaggggtat acgocgtgag atgtactgct gacgogcact gaggataggc tgggtgtgga aacgctggcc 2700
 gagcacgtga atgtactgct ootatcaaac attccacagg gtaactttac ggcacattg 2760
 gggatccctt aagaagaaca cgaacaaata atgaaaggtg ttgaaggacc ggtcgcgct 2820
 50 gtggacgctg tccagaacaa agcgaacgtg tgttggcgga aaagcctggt gcctgtcctg 2880
 gacactgccc gaactcagatt gacagcagag gactggagca ccataattac agcatttaag 2940
 gaggacagag cttactctcc agtgggtggc ttgaatgaaa tttgcacca gtactatgga 3000
 55 gttgacctgg acactggcct acagagctgg tggaaaggtg atggcgcaac aggtgocagg 3120
 cactgggata acagacactt gacatacctt cctgaagggg cagtggcata cgggcaagca ggcagttatc 3180
 ctggaaagcta aaatccaaac gctttctgtg ctggacaatg taattcctat caacogcagg 3240
 gcagaagaaa cctggtgggc tgaatcaag ccacgtcctg ctggtgagtg agtacaacct ggctttgcct 3300
 60 gtcaataaag taagagggta cactctgggt gtcaccgctg aatgtcacag gcgcgcatag gtcctacgac 3420

Ac.66

15/16

5

10

15

20

25

30

35

40

45

50

55

ctaagtttag gactgcccgc tgaogccggc aggttcgact tggctcttctg gaaatttoac 3480
 acggaattca gaattccacca ctaccagcag tgtgtcgacc agcccatgaa gctgcagatg 3540
 cttgggggag atgogctacg actgctaaaa cccggcggca tottgatgag agottacgga 3600
 tacgcogata aaatcagcga agccgttgtt tcttccttaa gcagaaagt tctgtctgca 3660
 agagtgttgc gcccggtttg tctcaccagc aatcacagaag tgttcttctg gttctccaac 3720
 tttgacaaag gaaagagacc ctctacogcta caccagatga ataccaagct gagtgcctg 3780
 tatgcogggag aagccatgca caccggccggg tgtgcaacct cctacagagt taagagagca 3840
 gacatagcca cgtgcacaga agoggtctgtg gttaacgcag ctacagcccg tggaaactgt 3900
 ggggatggcg tatgcagggc cgtggcgagag aatggccgt cagcctttaa gggagcagca 3960
 acaccagtgg gcacacttaa aacagtcatg tgccgctgtg aacccgtcat ccacgtgtg 4020
 gcgcctaatt tctctgcac gactgaagcg gaaggggacc gcgaattggc cgtgtctac 4080
 cgggcagtgg ccgcogaagt aaacagactg tcaactgagca gcgtagccat ccgctgctg 4140
 tccacaggag tgttcagcgg cgggaagagat aggtctgcagc aatccctcaa ccatctattc 4200
 acagcaattg acgcccaggc cgtgcagctg accatctact gcagagacaa agttggggag 4260
 aagaaaatcc aggaagccat tgacatgagg aoggtctgtg agttgctcaa tgatgacgtg 4320
 gagctgacca cagacttggc gaggatgcac cggacagca gctgggtggg tctgaagggc 4380
 tacagtacca ctgacgggtc gctgtactcg taacttgaag gtacgaatt caaccaggct 4440
 gctattgata tggcagagat actgacgttg tggcccagac tgcaaggagg gatccaaatg 4500
 atatgctat acgcgctggg cgaacaatg gacaaatca gatccaaatg tccggtgaa 4560
 gattccgatt tccacacacg toccogctgc gtgocgcta tgtgcgcta cgcattgaca 4620
 gcagaaaggc cgcgcgcct taggttaaac caagttaaaa gcattgggtg tgtctcatc 4680
 tttccctcc cgaatatcca tgtagatggg gtgcagaagg taaagtggc gaaggttctc 4740
 ctgttcgacc cgacggtacc ttcaagtggg agtcogcgga agtatgcgc atctacgacg 4800
 gacactcag atcggctggt acgaggggtt gacttggact ggaaccoga ctgctcttc 4860
 actgcacgag gctacccagt ttgcagctcg gtgacatcga ctgatctac ctgatctac 4920
 gagccaattg ctcccatagt agtgacggct gacgtacacc ctgaaccgc aggcacgcg 4980
 gacctggcgg ccagatgtgca cctgaaccc gcagaccatg tggacctoga gaaaccgat 5040
 cctccaccgc gcccggaagag agctgcatac ottgcctccc ggcggcgga ggcacccgtg 5100
 ccggcgccgc gaaagccgac gctgcctccc aggaactgct ttaggaacaa gctgccttg 5160
 accgttcggc actttgacga gacagaggtc gatcggttg otcocgggat taacttctga 5220
 gaattcgacg acgtcctgog actagggcgc goggggtgcat atattttctc ctccggacac 5280
 ggcagcggaac atttacaaca aaatccgtt aggcagcaca atctccagt cgcacaactg 5340
 gatgcggtcc agggaggaga aatgtaccog ccazaatttg atactgagag ggagaagctg 5400
 ttgctgctga aaatgcagat gcacccatcg gaggttaata agagtcgata ccagtctcgc 5460
 aaagtggaga acatgaagc caccgttggc caoaggtcca catogggggg cagattgtac 5520
 ccgggagcgg acgtaggcgc catccaaca tacggggttc ggtacccccc ccccggtgac 5580
 tccctacccg tgatogaag atctccaagc ccogagttag caatcgcagc gtgcaacgaa 5640
 tacctatcca gaatttacc tccagtgagc tegtacoga taacagatga atacgacgca 5700
 tacttggaca tggttgagc gtccgtatag tctgggaca gagcgacatt ctgcccggc 5760
 aagctccggt gctaccogaa acatcatgog taaccaccagc cgactgtacg bagtgccgc 5820
 cgttcaccc ttcagaacac actacagaac gtgctagcgg ccgccacca gagaaactgc 5880
 aacgtcacgc aaatgcgaga actaccacc atgggactcg tgggaagaa atgctaaaca acctatccg 6000
 tcaagcgc atgootgctc cggagaatat accaattga agggccgaa agctgctgc 6060
 ataaccactg agaactcac tacttatgtg ctgcaggagg ccagggaagc aagggccgaa 6120
 ttgttcgcta agaccacaa ccaagtcaact ccagggaagc aacacacaga ggaagaccc 6180
 gtgcacatga aacgagatgt taattcaagc agcgagacca cttacactgt gggcatccac 6240
 aaagtccagg taaggagact aatgctgtg ttacgoccta acgtgcacac attgtttgat 6300
 atgtcggcgg aagactttga cgcgatcatc gccctcact tccacccagg agacccggt 6360
 ctagagacgg acattgcata attcgacaaa agccaggac cactcctggc tcttaacagt 6420
 ttaantgatc tcgaagatct aggggtggat cagtacotgc tggacttgat cgaggcagcc 6480
 tttggggaaa tatocagctg tccactacca actggcaogc gcttcaagt oggagctatg 6540
 atgaaatcgg gcatgtttct gactttgttt attaacactg ttttgaaat caccatagca 6600
 agcagggtag tggagcagag actcactgac cccgctgtg cggccttcac cggcgacgac 6660
 aacatcgttc acggagtgat ctccgacaag gtcctgtgc agaggtgcgc gtcgtgggc 6720
 aacatggagg tgaagatcat tgacgctgtc atgggcgaaa aaccccata tttttgtgg 6780
 ggattcatag tttttgacag cgtcacacag accgocctgc gtgtttcaga cccacttaag 6840
 cgcctgttca agttgggtaa ggcgttaaca agcaggacga agacaggcga 6900
 cgagcactga gtgacgaggt tagcaagtgg ttcgggacag gcttggggg 6960

fat 60

16/16

5

10

15

20

09190246-11396

gtggcactaa	catctaggta	tgaggtagag	gggtgcataa	gtatcctcat	agccatggcc	7020
accttgggga	gggacattaa	ggcgtttaag	aaattgagag	gacctgttat	acacotctac	7080
ggcggtccta	gattgggtgg	ttatatacaca	gaattctgat	tggtatcatag	cgcactatta	7140
taggatccag	accccggtta	attaattgaa	ttacatccct	acgcaaacgt	tttacggcgg	7200
cgggtggcgc	cggcgcccg	eggcccgctc	ttggccggtg	caggcactc	oggtggctcc	7260
cgtcgtcccc	gaattccagg	ccagcagat	gcagcaactc	atcagcgcg	taaattgcgt	7320
gacattgaga	cagaacgcma	ttgctcctgc	taggcctccc	aaaccaaga	agaagaagac	7380
aaacaaacca	aagccgaaaa	cgcagcccaa	gaagatcaac	ggaaaaagc	agcagcaaaa	7440
gaagaaagac	aagcaagccg	acaagaagaa	gaagaaaccc	ggaaaaagag	aaagaatgtg	7500
catgaagatt	gaatttgact	gtatcttctg	atgcggctag	ccacagtac	gtagtgtttc	7560
cagacatgtc	gggcacccga	ctatcatggg	tgacagaaat	ctcgggtggt	ctggggggct	7620
tgcacatogg	cgctatcctg	gtgctgggtg	tggtcacttg	cattgggctc	cgcagataag	7680
ttagggtagg	caatggcatt	gatatagcaa	gaatttgaa	aacagaaaaa	gttagggtaa	7740
gcaatggcat	acacccatca	ctgtataact	tgtaacaaag	cgcacacaga	cctgcgcaat	7800
tgcccccggtg	gtccgcctca	cggaacctcg	gggcaactca	tattgacaca	ttatttggca	7860
ataattggaa	gcttacataa	gcttaattcg	acgaataatt	ggatttttat	tttattttgc	7920
aattgggtttt	taattatttcc	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	7980
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	ctagcgggtc	ggcatggcat	ctccacctcc	8040
tgcgggtccg	acctgggcat	cgaaggag	acgcacgtcc	actcggatgg	ctaagggaga	8100